Skip to content

MDMA: all studies

Page 302 of 345: studies 3,011 to 3,020 of 3,446, newest first. Back to the MDMA overview

Research

Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment

Drugs Education Prevention and Policy April 30, 2021 Johannes Thrul, Albert Garcia‐romeu 78 citations

Growing research on potential therapeutic applications of highly restricted Schedule I hallucinogens, including the ‘classic psychedelic’ psilocybin, and the entactogen 3,4-Methylenedioxymethamphet...

DOI: 10.1080/09687637.2021.1897331 (opens in new tab) Psilocybin Hallucinogen Mental health Clinical psychology +1

A Qualitative Study of Intention and Impact of Ayahuasca Use by Westerners

April 1, 2021 Geoff J. Bathje, Jon Fenton, Daniel Pillersdorf et al. 23 citations preprint

Ayahuasca has gained the attention of researchers over the past decade as psychedelic-assisted therapy for MDMA and psilocybin have progressed through FDA approved clinical trials. In spite of the increase in research, there are relatively few clinical studies of ayahuasca and little qualitative research on the therapeutic or healing uses of psychedelics in general. The present study included...

Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm

Australian & New Zealand Journal of Psychiatry March 21, 2021 Daniel Perkins, Jerome Sarris, Susan L. Rossell et al. 53 citations

The medical use of psychedelic substances (e.g. psilocybin, ayahuasca, lysergic acid diethylamide and 3,4-methylenedioxymethamphetamine) is attracting renewed interest, driven by a pressing need for research and development of novel therapies for psychiatric disorders, as well as promising results of contemporary studies. In this Viewpoint, we reflect upon the ‘Clinical Memorandum on...

DOI: 10.1177/0004867421998785 (opens in new tab) Psilocybin Mental health Psychotherapist Hallucinogen

New psychoactive substances in Taiwan: The current situation and initiative for rational scheduling.

Journal of Food and Drug Analysis March 15, 2021 Wen-Jing Yu, Linda B. Cottler, Jih-Heng Li 13 citations

Use of New Psychoactive Substances (NPS) has posed a global threat to public health and the security of the population. As of December 2019, the NPS items identified in total have outnumbered by three to one the controlled substances listed in the 1961 and 1971 UN Drug Conventions. However, most of these NPS have not been scheduled by the United Nations because of their easy modification on the...

DOI: 10.38212/2224-6614.3225 (opens in new tab) Full text (opens in new tab) Addiction Psychoactive substances Traditional controlled drugs Drug misuse +11

Session on Psychedelics Sure to Be Enlightening

Psychiatric News March 1, 2021 Nick Zagorski

Back to table of contents Previous article Next article APA & MeetingsFull AccessSession on Psychedelics Sure to Be EnlighteningNick ZagorskiNick ZagorskiSearch for more papers by this authorPublished Online:2 Mar 2021https://doi.org/10.1176/appi.pn.2021.3.14AbstractLeaders in psychedelic research will discuss the therapeutic potential of psychedelic compounds in psychiatry and important...

Trójca Święta i doświadczenie mistyczne

February 2, 2021 J. Królikowski

The mystery of the Holy Trinity constitutes a transcendental and original principle of the history of salvation and the first subject of Christian faith. Christian faith and Christian life are both shaped in relation to this mystery. Therefore we can speak about the primacy of the Holy Trinity in the faith, which finds its expression in the gradual development and in the overall shape of...

Peak-experience and the entheogenic use of cannabis in world religions

Journal of Psychedelic Studies January 15, 2021 Mark S. Ferrara 24 citations

AbstractThis paper demonstrates that cannabis can evoke “peak-experiences”—the name psychologist Abraham Maslow gave to fleeting moments of expanded perception indicative of self-transcendence—when used alongside more traditional religious practices such as meditation, fasting, contemplative prayer, and sacramental ritual. For that reason, religious seekers around the globe have deployed...

PRIMER EPISODIO PSICÓTICO TRAS CONSUMO DE 4-BROMO-2,5-DIMETOXIFENILETILAMINA (2C-B), ÉXTASIS Y THC: A PROPÓSITO DE UN CASO

Libro Comunicaciones 2021

4-bromo-2,5-dimetoxifeniletilamina, también conocido como 2C-B, "tussi", "nexus" o "cocaína rosa" es una droga sintética del grupo de las feniletilaminas, con efectos alucinógenos y euforizantes, debido a su efecto como agoniza parcial de receptores 5HT-2A, 5HT-2B y 5HT-2C, cuyo consumo se ha extendido en los últimos años. Presentamos el caso de una paciente de 22 años sin antecedentes...

Culture, Context, and Community in Contemporary Psychedelic Research

Philosophy, Psychiatry, & Psychology 2021 Brian D. Earp, David B. Yaden 4 citations

Culture, Context, and Community in Contemporary Psychedelic Research Brian D. Earp (bio) and David B. Yaden (bio) Psychedelics require cross-cultural, interdisciplinary study, and we were happy to see a contribution from the field of medical anthropology. Such a study holds the promise of characterizing the ways in which psychedelics are situated in contemporary societies, both within and...

DOI: 10.1353/ppp.2021.0033 (opens in new tab) Situated Criticism Context archaeology Aesthetics +1

Pharmacology and Neurotoxicity of 5-MeO-DIPT

Handbook of Neurotoxicity 2021 Krystyna Gołembiowska

Psychedelics are drugs that alter consciousness and affect human psyche. 5-Methoxy- N,N -diisopropyltryptamine (5-MeO-DIPT) emerged in the recreational drug market with the street name “foxy” and has been increasingly used as a substitute for methylenedioxymethamphetamine (MDMA) Methylenedioxymethamphetamine (MDMA) . 5-MeO-DIPT is a competitive inhibitor of the serotonin (5-HT) transporter...